Literature DB >> 6415100

Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins.

D F Sahm, C N Baker, R N Jones, C Thornsberry.   

Abstract

Mueller-Hinton (MH) agar media from various commercial sources, either supplemented or not supplemented with 5% sheep blood, were studied to determine their effect on disk diffusion susceptibility testing results obtained with 90 strains of group D streptococci and four cephalosporins. The cephalosporins investigated included cephalothin, cefamandole, moxalactam, and cefotaxime. Results showed that a number of Streptococcus faecalis and Streptococcus faecium strains were susceptible to cephalothin, cefamandole, and cefotaxime, but the number varied with both the commercial source and blood content of the MH medium used. Regardless of the MH medium used, none of the S. faecalis or S. faecium strains were found to be susceptible to moxalactam. The apparently medium-associated variations in the number of strains susceptible to cephalothin, cefamandole, and cefotaxime were largely due to minor discrepancies (one result being intermediate) among the various types of MH media used. However, major discrepancies (one result being resistant and the other susceptible or vice versa) were observed when S. faecalis strains were tested against cefotaxime. These major discrepancies were associated with both the commercial source of the MH medium and the blood content of the medium.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415100      PMCID: PMC270919          DOI: 10.1128/jcm.18.4.858-865.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

2.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

3.  Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole.

Authors:  J P Sosna; P R Murray; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

4.  Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

5.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

6.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  T Kamimura; Y Matsumoto; N Okada; Y Mine; M Nishida; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

  7 in total
  8 in total

1.  Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis.

Authors:  D F Sahm; C N Baker; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

Review 2.  Microbiological investigation of cephalosporins.

Authors:  J M Hamilton-Miller
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens.

Authors:  P H Karakusis; G M Trenholme; S Levin
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  False susceptibility of enterococci to aminoglycosides with blood-enriched Mueller-Hinton agar for disk susceptibility testing.

Authors:  R D Jenkins; S L Stevens; J M Craythorn; T W Thomas; M E Guinan; J M Matsen
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

5.  Antimicrobial susceptibility of Pediococcus spp. and genetic basis of macrolide resistance in Pediococcus acidilactici HM3020.

Authors:  J Tankovic; R Leclercq; J Duval
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 6.  Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.

Authors:  R N Jones
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci.

Authors:  B J Buschelman; R N Jones; M J Bale
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

8.  Effects of different test conditions on MICs of food animal growth-promoting antibacterial agents for enterococci.

Authors:  P Butaye; L A Devriese; F Haesebrouck
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.